Get the Stockscreener App
8.49
3.52%
-0.31
After Hours:
8.35
-0.14
-1.65%
Evommune Inc stock is traded at $8.49, with a volume of 541.05K.
It is down -3.52% in the last 24 hours and down -38.43% over the past month.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
See More
Previous Close:
$8.80
Open:
$8.78
24h Volume:
541.05K
Relative Volume:
0.63
Market Cap:
$308.12M
Revenue:
$10.00M
Net Income/Loss:
$-75.99M
P/E Ratio:
-3.5563
EPS:
-2.3873
Net Cash Flow:
$-80.36M
1W Performance:
-12.02%
1M Performance:
-38.43%
6M Performance:
-63.29%
1Y Performance:
+0.00%
1-Day Range:
$8.33
$8.78
1-Week Range:
$8.25
$9.865
52-Week Range:
$8.25
$33.20
Evommune Inc Stock (EVMN) Company Profile
Name
Evommune Inc
Sector
Industry
Phone
(650) 223-7745
Address
1891 PAGE MILL RD, PALO ALTO
Compare EVMN vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVMN
Evommune Inc
|
8.49 | 308.12M | 10.00M | -75.99M | -80.36M | -2.3873 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Evommune Inc Stock (EVMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-26 | Resumed | Oppenheimer | Outperform |
| Jan-22-26 | Initiated | Oppenheimer | Outperform |
| Jan-08-26 | Initiated | Raymond James | Strong Buy |
| Jan-06-26 | Initiated | H.C. Wainwright | Buy |
| Dec-01-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-01-25 | Initiated | Evercore ISI | Outperform |
| Dec-01-25 | Initiated | Leerink Partners | Outperform |
| Dec-01-25 | Initiated | Morgan Stanley | Overweight |
| Dec-01-25 | Initiated | William Blair | Outperform |
View All
Evommune Inc Stock (EVMN) Latest News
Evommune (EVMN) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress - biospace.com
Evommune Reports Phase 2a EVO301 Atopic Dermatitis Data at EADV 2026 via 8-K Filing - Kalkine Media
Evommune to present phase 2a atopic dermatitis data at EADV By Investing.com - Investing.com Nigeria
Evommune (EVMN) Edges Higher: Shares Gain 1.59% to $9.60 as Buyers Hold SupportCup and Handle - siam.in
Evommune: Pipeline Reset After EVO756 Failure, All Eyes On EVO301 (NYSE:EVMN) - Seeking Alpha
Analysts Have Conflicting Sentiments on These NA Companies: Evommune, Inc. (EVMN) and Douglas AG (OtherDOUDF) - The Globe and Mail
Cantor Fitzgerald reiterates Evommune stock rating at Overweight - Investing.com
Evommune (EVMN) Drops EVO756 for Eczema. Can EVO301 Carry the Pipeline? - finance.yahoo.com
EVMN: Advancing novel therapies in atopic dermatitis and migraine, with strong funding and pipeline momentum - TradingView
Evommune Releases Updated Corporate Presentation Compliant with Regulation FD - Kalkine Media
Form 8K Evommune Inc For: 15 September By Investing.com - Investing.com India
Evommune posts updated corporate presentation outlining pipeline progress, cash runway and 2027–2028 milestones - TradingView
Evommune（NYSE: EVMN）が現金を賢明に活用することを期待しています。 - Moomoo
Analysts Offer Insights on NA Companies: Chime Financial, Inc. Class A (CHYM), ServiceTitan, Inc. Class A (TTAN) and Evommune, Inc. (EVMN) - The Globe and Mail
Analysts Offer Insights on NA Companies: Evommune, Inc. (EVMN), Inhibrx Biosciences Inc (INBX) and Circle Internet Group, Inc. Class A (CRCL) - The Globe and Mail
Evommune stock maintains Buy rating despite trial setback By Investing.com - Investing.com Nigeria
RBC cuts Evommune stock price target on drug trial setback By Investing.com - Investing.com Australia
Evommune Scraps Itch Drug After Second Phase 2 Failure, Stock Slides 18% - finance.biggo.com
EVMN Maintains Rating by Leerink Partners -- Price Target Lowered to $22 - GuruFocus
Evommune Drops AD Program Following Phase 2B Trial Failure - The Dermatology Digest
Why this company's stock took a hit just 10 months after its IPO - The Business Journals
Evommune’s EVO-756 fails dermatitis study; focus on migraine - BioWorld News
Stifel reiterates Evommune stock rating after phase 2b trial miss By Investing.com - Investing.com Nigeria
Stifel reiterates Evommune stock rating after phase 2b trial miss - Investing.com
Evommune Reports EVO756 Phase 2b Trial Failure in Atopic Dermatitis, Halts Development for This Indication - Kalkine Media
Evommune (NYSE:EVMN) Price Target Lowered to $21.00 at Royal Bank Of Canada - MarketBeat
RBC cuts Evommune stock price target on drug trial setback - Investing.com India
Why is Evommune stock plunging today? By Investing.com - Investing.com Australia
Evommune's (EVMN) Neutral Rating Reaffirmed at HC Wainwright - MarketBeat
Evommune stock maintains Buy rating despite trial setback - Investing.com
Evommune Halts Atopic Dermatitis Program Following Trial Failure - Benzinga
Why is Evommune stock sliding 13% today? - Investing.com
RBC Cuts Price Target on Evommune to $21 From $29, Keeps Outperform, Speculative Risk - marketscreener.com
Why is Evommune stock sliding 13% today? By Investing.com - Investing.com Canada
Why is Evommune stock tumbling today? By Investing.com - Investing.com Canada
Evommune's EVO756 suffers second Phase IIb setback in two months with AD miss - AllSci
Evommune’s EVO756 fails phase 2b trial in atopic dermatitis By Investing.com - Investing.com India
Evommune stock tumbles after trial misses primary endpoint By Investing.com - Investing.com South Africa
Evommune stock tumbles after trial misses primary endpoint - investing.com
Why Is EVMN Stock Down 13% After-Hours? - Yahoo Finance
Evommune scraps eczema drug after trial miss, shares plunge - Reuters
Evommune’s EVO756 fails phase 2b trial in atopic dermatitis - investing.com
Why is Evommune stock plunging today? - investing.com
Evommune Inc Stock (EVMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):